To include your compound in the COVID-19 Resource Center, submit it here.

5-HT2C receptor agonist: VER terminated development of its 5-HT2C receptor agonist to treat obesity. The company said the decision was made with partner Roche (

Vernalis Group plc (LSE:VER), Wokingham, U.K.
Product: 5-HT2C

Read the full 83 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE